SHM Joins Multi-Stakeholder Letter Supporting the MAT Act
SHM joins over 100 medical societies and patient advocacy groups supporting the inclusion of the “Mainstreaming Addiction Treatment Act” to the broader “Restoring Hope for Mental Health and Well-Being Act.”
SHM Supports the Reintroduction of the Mainstreaming Addiction Treatment Act
SHM supports the reintroduction of the Mainstreaming Addiction Treatment Act. This legislation will eliminate the X-Waiver prescribing requirement for buprenorphine, a lifesaving medication used to treat opioid use disorder (OUD).
SHM Joins Multi-stakeholder Letter Urging Congress to Eliminate the X-Waiver
SHM and other stakeholders sent a letter to Congressional leaders, urging for the elimination of the X-waiver. Eliminating the X-waiver will expand access to buprenorphine, a lifesaving treatment for opioid-use disorder (OUD).
SHM Joins Multi-stakeholder Letter Urging Congress to Remove Restrictions on Buprenorphine
SHM joined a multi-stakeholder letter urging Congress to expand access to buprenorphine. The letter urged Congress to include legislation to address the opioid epidemic in the upcoming COVID relief package.
SHM Joins Multi-Stakeholder Letter Supporting the Elimination of the X-Waiver
SHM joined a multi-stakeholder letter urging the Acting Secretary of Health and Human Services (HHS) to finalize guidelines that would expand access to buprenorphine.
SHM Sends Letter to Energy and Commerce Republicans on Opioid Use Disorder Treatment
SHM responds to the House Energy and Commerce Republicans’ request for information regarding opioid and substance use disorder treatment. This letter focuses specifically on the need to deregulate of buprenorphine, a lifesaving medication that helps treat opioid use disorder.
SHM Supports the Mainstreaming Addiction Treatment Act
The Mainstreaming Addiction Treatment Act (H.R. 2482) will increase access to buprenorphine, a lifesaving addiction treatment, by eliminating the “X Waiver” DEA certificate and the provider-patient cap. This legislation will help reduce stigma associated with treatment and will remove barriers to the use of buprenorphine for treating opioid use disorder.
Comments on the 2019 Outpatient Prospective Payment System
SHM submits comments on the HCAHPS survey pain communication questions in the 2019 Outpatient Prospective Payment System Rule.
SHM Submits a Letter of Support for Opioid Legislation
SHM sent a support letter to Reps. Blumenauer and Mullin for their legislation, the Overdose Prevention and Patient Safety Act.
SHM Publishes Policy Statement Addressing the Opioid Epidemic
SHM urges Congress to take action to address the opioid crisis facing the United States.